Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics
The FDA cleared Processa's IND for a Phase 2 study of VT-7208, its lead oral BTK inhibitor, in chronic spontaneous urticaria -- the first of three planned Phase 2 programs alongside food allergy and relapsing multiple sclerosis. The company also struck a research collaboration with Generian Pharmaceuticals for an oral FcRn antagonist program targeting IgG-mediated autoimmune diseases, and appointed Dr. Sheila Gujrathi as Executive Chair.
Key figures
- Drug Name
- VT-7208
- Phase Of Trial
- Phase 2
- Cash runway
- into the second half of 2029
- Trial duration
- 12 weeks
- Private placement
- $200 million
- Planned enrollment
- approximately 120 adults
- Csu patient population
- 1.6 to 2 million U.S. adults
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.